Mealey's (April 3, 2023, 8:01 AM EDT) -- BOSTON — A federal judge in Massachusetts ruled that dismissal of federal securities law claims in a class action against a biotechnology company and certain of its current and former senior executives alleging that the defendants misrepresented the commercial viability of an Alzheimer’s disease treatment drug is necessary because the lead plaintiff has failed to sufficiently plead any actionable misstatement or omissions or scienter in stating its claims....